medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 3

<< Back Next >>

Ann Hepatol 2005; 4 (3)

TP53 Abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma

Moreno M, Pimentel F, Gazdar AF, Wistuba II, Miquel JF

Language: English
References: 40
Page: 192-199
PDF size: 153.57 Kb.


Text Extraction

Background: Gallbladder carcinoma (GBC) is a frequent neoplasm in Hispanic and native American populations. GBC is preceded by gallstones, chronic cholecystitis and dysplastic changes of the gallbladder epithelium. The knowledge of the molecular events involved in its pathogenesis is scarce. Aims: We investigated the role of TP53 inactivation in the sequential pathogenesis of GBC. Methods: Invasive tumor-, dysplastic- and histologically normal GB epithelial-cells were obtained from archival formalin-fixed tissues from GBC and GB from gallstone patients without GBC. Normal GB epithelia from 5 non-gallstone specimens were also studied. DNA extracted was examined for loss of heterozygosity (LOH) using 2 microsatellite markers and for TP53 mutations at exons 5 to 8. Results: GBCs demonstrated a high frequency of LOH (81%) and mutation (67%), and both abnormalities indicating gene inactivation were detected in 52%. Similar frequency of TP53 abnormalities and gene inactivation (38%) were detected in their accompanying normal and dysplastic epithelia. Noteworthy, one third of normal and dysplastic epithelia obtained from GBs of gallstone patients without GBC demonstrated either TP53 allele loss or mutation, but gene inactivation was less frequent (11%). Most mutations affected exons 5 and 7, and they were more frequently missense point mutations. The same TP53 mutation was detected in only a subset (27%) of comparisons between non-malignant epithelia adjacent to GBCs, indicating that TP53 mutation occurs independently at several epithelial foci. Conclusions: These findings indicate that TP53 abnormalities are early and frequent events in the pathogenesis of GBC, starting from chronic cholecystitis.


REFERENCES

  1. Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba, II, Alonso de Ruiz P, Aristi Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51: 349-64.

  2. Wistuba, II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 237-44.

  3. Tang M, Baez S, Pruyas M, Diaz A, Calvo A, Riquelme E, Wistuba, II. Mitochondrial DNA mutation at the D310 (displacement loop) mononucleotide sequence in the pathogenesis of gallbladder carcinoma. Clin Cancer Res 2004; 10: 1041-6.

  4. Albores-Saavedra J, Henson DE. Tumors of gallbladder and extrahepatic bile ducts. Fascicle 23, third edit. Armed Forces Institute of Pathology, 2000.

  5. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.

  6. Greenblatt MS, Bennett WP, Hollatein M, Harris CC. Mutations in the p53 tumor supressor gene: clue to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.

  7. Harris CC. p53 Tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996; 17: 1187-1198.

  8. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996; 77: 452-8.

  9. Hanada K, Itoh M, Fujii K, Tsuchida A, Hirata M, Iwao T, Eguchi N, Sasaki T, Matsubara K, Kajiyama G. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. Eur J Cancer 1997; 33: 1136-40.

  10. Fujii K, Yokozaki H, Yasui W, Kuniyasu H, Hirata M, Kajiyama G, Tahara E. High frequency of p53 gene mutation in adenocarcinomas of the gallbladder. Cancer Epidemiol Biomarkers Prev 1996; 5: 461-6.

  11. Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T. Correlation of p53 protein expression with gene mutation in gall- bladder carcinomas. Pathol Int 1997; 47: 525-30.

  12. Jonas S, Springmeier G, Tauber R, Wiedenmann B, Gessner R, Kling N, Lobeck H, Fieger C, Bechstein WO, Neuhaus P. p53 hot-spot mutational analysis in advanced Western gallbladder carcinoma. World J Surg 1997; 21: 768-72.

  13. Yokoyama N, Hitomi J, Watanabe H, Ajioka Y, Pruyas M, Serra I, Shirai Y, Hatakeyama K. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev 1998; 7: 297-301.

  14. Roa I, Melo A, Roa J, Araya J, Villaseca M, de Aretxabala X. [P53 gene mutation in gallbladder cancer]. Rev Med Chil 2000; 128: 251-8.

  15. Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J, Gazdar AF. Allele specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995; 55: 2511-2515.

  16. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol 1993; 170: 67-72.

  17. Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer 1994; 74: 1542-5.

  18. Lee CS, Pirdas A. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. Pathology 1995; 27: 117-20.

  19. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology 1995; 22: 774-9.

  20. Wistuba, II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol 1996; 27: 360-5.

  21. Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S, Saitoh Y. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 1996; 43: 521-6.

  22. Roa I, Villaseca M, Araya J, Roa J, de Aretxabala X, Melo A, Ibacache G. p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 1997; 31: 226-30.

  23. Wistuba, II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF. Comparison of molecular changes in lung cancers in HIV-positive and HIV- indeterminate subjects. JAMA 1998; 279: 1554-1559.

  24. Jones MH, Nakamura Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosom Cancer 1992; 5: 89-90.

  25. Futreal PA, Barrett JC, Wiseman RW. An Alu polymorphism intragenic to the PT53 gene. Nucleic Acids Research 1991; 19: 6977.

  26. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. Science 1985; 230: 1242-6.

  27. Winter E, Yamamoto F, Almoguera C, Perucho M. A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-Ki-ras allele in human tumor cells. Proc Natl Acad Sci U S A 1985; 82: 7575-9.

  28. Wistuba, II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, Gazdar AF. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 1997; 57: 3154-8.

  29. Wistuba, II, Maitra A, Carrasco R, Tang M, Troncoso P, Minna JD, Gazdar AF. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Br J Cancer 2002; 87: 432-40.

  30. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991; 51: 3075-3079.

  31. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DJ, Tarone RE, Brash DE. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A 1996; 93: 14025-9.

  32. Vanin K, Scurry J, Thorne H, Yuen K, Ramsay RG. Overexpression of wild-type p53 in lichen sclerosus adjacent to human papillomavirus-negative vulvar cancer. J Invest Dermatol 2002; 119: 1027-33.

  33. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999; 22: 106-9.

  34. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-14.

  35. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a “gain of function” phenotype. Ann N Y Acad Sci 1995; 768: 111-28.

  36. Rideout WMd, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990; 249: 1288-90.

  37. Campomenosi P, Conio M, Bogliolo M, Urbini S, Assereto P, Aprile A, Monti P, Aste H, Lapertosa G, Inga A, Abbondandolo A, Fronza G. p53 is frequently mutated in Barrett’s metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev 1996; 5: 559-65.

  38. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60: 3333-7.

  39. Apstein MD, Carey MC. Pathogenesis of cholesterol gallstones: a parsimonious hypothesis. Eur J Clin Invest 1996; 26: 343-52.

  40. Ko CW, Lee SP. Gallstone formation. Local factors. Gastroenterol Clin North Am 1999; 28: 99-115.




2020     |     www.medigraphic.com